| Literature DB >> 31000591 |
Daisuke Sugiura1, Takumi Maruhashi1, Il-Mi Okazaki1, Kenji Shimizu1, Takeo K Maeda1, Tatsuya Takemoto2, Taku Okazaki3.
Abstract
Targeted blockade of PD-1 with immune checkpoint inhibitors can activate T cells to destroy tumors. PD-1 is believed to function mainly at the effector, but not in the activation, phase of T cell responses, yet how PD-1 function is restricted at the activation stage is currently unknown. Here we demonstrate that CD80 interacts with PD-L1 in cis on antigen-presenting cells (APCs) to disrupt PD-L1/PD-1 binding. Subsequently, PD-L1 cannot engage PD-1 to inhibit T cell activation when APCs express substantial amounts of CD80. In knock-in mice in which cis-PD-L1/CD80 interactions do not occur, tumor immunity and autoimmune responses were greatly attenuated by PD-1. These findings indicate that CD80 on APCs limits the PD-1 coinhibitory signal, while promoting CD28-mediated costimulation, and highlight critical components for induction of optimal immune responses.Entities:
Year: 2019 PMID: 31000591 DOI: 10.1126/science.aav7062
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728